August 13 (5:00PM) - 19 (9:00PM), 2020
National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat)
Hosted by Epizyme
WEBINAR - Multiple Broadcast Times
Learn more about a new treatment option for your relapsed or refractory follicular lymphoma (FL) patients
In this Live Broadcast, Dr. Pagel, Dr. Burke, and Dr. Kurtin will:
- Review the Prescribing Information for this new treatment available for relapsed or refractory FL patients
- Present clinical safety and efficacy data in this patient population
- Provide important dosing and patient counseling information
- Discuss a hypothetical patient case study